Sosei Heptares Acquires Idorsias Pharmaceuticals Business in Japan and APAC

Sosei Heptares has announced the acquisition of Idorsia's Pharmaceuticals business in Japan and the Asia-Pacific region, excluding China. This strategic move marks a significant step towards Sosei Heptares' transformation into a fully integrated biopharmaceutical powerhouse.

Sosei Group's acquisition of Idorsia Pharmaceuticals Japan and Idorsia Pharmaceuticals Korea is set to bring significant expertise in drug development and commercialisation to Sosei Heptares, along with a strong market presence in Japan and the Asia-Pacific (APAC) region, excluding China.

As part of the transaction, Sosei Heptares will obtain select rights for Japan and APAC (ex-China) to two GPCR-targeted products: PIVLAZ® and daridorexant, and exclusive opt-ins for the Phase 3 cenerimod and lucerastat programmes. 

Additionally, gain selected rights to up to five more clinical-stage programmes from Idorsia's development portfolio. This infusion of products and programmes will expand Sosei Heptares' drug pipeline and enhance its capabilities to develop and commercialise innovative medicines in the region.

The strategic transaction leverages three sources of innovation for Sosei Heptares: their own wholly owned discovery and early development pipeline, selected clinical candidates from Idorsia's pipeline, and in-licencing of clinical product candidates from third parties in Japan and APAC (ex-China).

One of the highlights of the acquisition is gaining rights to Idorsia's exciting pipeline of medicines, including the lead product PIVLAZ® (clazosentan), which has already been commercially launched and has seen rapid sales growth in Japan since its introduction in April 2022.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!